The report covers the fiscal years 2017 and 2018
The third Hovione Sustainability Report has been published today, which aims to respond to the expectations of our main stakeholders.
The Sustainability Report covers the fiscal years 2017 and 2018 and the four manufacturing sites.
We have been complying with the Global Reporting Initiative Standards since 2015. And in 2017 we were certified as a B Corp, and we strive to improve our rating. We have the right attitude and we make efforts to improve.
Find more about Sustainability at Hovione
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
in-PharmaTechnologist, September 3, 2019
Pharmaceutical Technology, September 2, 2019